Wegovy Side Effects in Women: What's Normal, What's Hair Loss, What's Serious

What are the most common Wegovy side effects?

Semaglutide slows stomach emptying and dampens appetite signals in the brain, and nearly everything reported in Wegovy's own clinical trial program traces back to that single mechanism. In STEP 1 — the pivotal trial behind Wegovy's original approval — nausea affected 44% of participants on the drug, compared with 16% on placebo. Diarrhea, vomiting, and constipation followed close behind.

• Nausea — the most common complaint, reported by 44% of trial participants versus 16% on placebo, usually strongest in the days right after each dose increase
• Diarrhea — 30% of participants
• Vomiting — 24%
• Constipation — 24%
• Abdominal pain — 20%
• Fatigue, headache, or mild dizziness, especially if food intake drops sharply

None of that reflects anything gone wrong. It's the drug doing what it's designed to do, delivered on a titration schedule specifically so the gut has time to adjust. Roughly 4.3% of Wegovy-treated participants across the drug's chronic weight-management trials stopped altogether because of a GI side effect, versus 0.7% on placebo — a real number, but one that means most people who experience these symptoms stay on treatment.

The oral tablet, FDA-approved in December 2025 as the first oral GLP-1 medication approved for chronic weight management, works through the same mechanism and reports a broadly similar GI profile in its own trials. What's different is the routine: it's taken once daily on an empty stomach, with roughly a 30-minute wait before eating or taking most other medications, because food changes how much of the dose actually absorbs. Missing that window doesn't create a new side effect — it just risks getting less of the intended dose.

Is Wegovy actually safe?

Wegovy carries its own FDA approval for chronic weight management, and that detail matters more than it might seem. Ozempic — the same molecule at a lower maximum dose — is approved only for type 2 diabetes; using it for weight loss is off-label, and its safety reasoning for that use borrows from Wegovy's own data. Wegovy doesn't have that problem. Its safety profile comes directly from the STEP trial program, the studies Novo Nordisk ran specifically to support this indication, plus SELECT, a cardiovascular-outcomes trial that followed more than 17,000 people with established heart disease for several years. For the parallel off-label picture on the same molecule, see Ozempic's side effects — though those numbers reflect Ozempic's diabetes-trial population, not Wegovy's own.

Across Wegovy's chronic weight-management trials, 6.8% of people on the drug stopped treatment permanently because of a side effect, compared with 3.2% on placebo. That gap is mostly explained by the GI symptoms above. SELECT extended the safety picture further, over several years, in a different population — people with existing cardiovascular disease rather than obesity alone — and found semaglutide reduced serious cardiovascular events, a separate question from side effects but relevant because it's the largest, longest safety dataset Wegovy has.

Does Wegovy cause hair loss?

There's no established mechanism by which semaglutide acts on hair follicles directly. What happens instead, in a minority of people, is telogen effluvium — a temporary, diffuse shedding pattern triggered by rapid weight loss itself, whatever caused it. Losing weight quickly pushes more hair follicles than usual out of their growth phase and into a resting one at the same time; months later, that resting hair sheds together instead of gradually.

In STEP 1, alopecia was reported by 3% of participants on Wegovy, versus 0.9% on placebo — a real difference, but a small one. Longer follow-up, including the two-year STEP 5 extension, points to hair-loss reporting staying in that same rough range rather than climbing the longer someone stays on treatment, though the precise multi-year figure is reported less consistently across sources than the STEP 1 number, so it's worth reading as directionally reassuring rather than exact. The pattern tying hair loss to weight loss itself, rather than the drug, also shows up inside the trial data: people who lost more than 20% of their body weight reported hair loss at about 5.3%, roughly double the rate reported by those who lost less weight.

Timing follows a fairly predictable arc. Shedding tends to start a few months in, often peaking around months four to six, and it's self-limiting for most women — hair density typically recovers over the following six to twelve months, even for those who stay on the medication. If you're already noticing perimenopausal thinning, that overlapping mechanism is worth understanding on its own terms; see perimenopause hair loss for what else can be driving it.

What are the worst, most serious side effects of Wegovy?

A shorter, less common list sits below the everyday GI complaints — the reason Wegovy carries the warnings it does, drawn from its own FDA prescribing information.

• Thyroid C-cell tumors — a boxed warning based on rodent studies, where semaglutide caused thyroid C-cell tumors at clinically relevant exposures; whether that translates to humans hasn't been established, and Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The FDA asks prescribers to counsel patients to watch for a neck lump, persistent hoarseness, trouble swallowing, or shortness of breath
• Gallbladder disease — cholelithiasis (gallstones) occurred in 1.6% of Wegovy-treated adults in the drug's own trials, versus 0.7% on placebo; cholecystitis followed at 0.6% versus 0.2%. Both are thought to trace back to rapid weight loss itself rather than a direct drug toxicity
• Pancreatitis — a warning across the GLP-1 class, though in SELECT, Wegovy's largest safety trial, confirmed pancreatitis occurred in 0.3% of both the drug and placebo groups — essentially even. Still monitored closely, and a personal history of pancreatitis typically steers someone away from this drug class
• Hypoglycemia — a meaningful risk if Wegovy is combined with insulin or a sulfonylurea, most relevant for the share of Wegovy patients who also have type 2 diabetes; a prescriber will typically lower the other medication's dose first
• Acute kidney injury — most reported cases trace back to dehydration from vomiting or diarrhea rather than a direct kidney effect, which is why staying ahead of fluid losses during a rough stretch matters

Does Wegovy cause cancer?

Worth answering directly, because the boxed warning often gets summarized online as simply "cancer risk," which overstates it. What the FDA warning specifically covers is medullary thyroid carcinoma, a rare thyroid cancer subtype, based on rodent studies where semaglutide caused thyroid C-cell tumors at clinically relevant exposures. It doesn't extend to the far more common thyroid cancer types, and no confirmed human case of semaglutide causing medullary thyroid carcinoma has been reported, years into the drug's use.

Zooming out further, recent meta-analyses across the whole GLP-1 drug class have generally found no increase in overall cancer incidence, and some data even points toward lower risk for certain obesity-related cancers — plausibly because sustained weight loss itself lowers cancer risk, independent of the drug. Large real-world studies looking specifically at pancreatic and thyroid cancer haven't turned up a clear signal tied to GLP-1 use either. None of that closes the book permanently; researchers are still watching this class as more years of exposure accumulate. As of today, though, there's no established causal link between Wegovy and cancer in humans.

The practical takeaway is narrower than the headline fear. If you have a personal or family history of medullary thyroid carcinoma or MEN 2, Wegovy isn't an option, full stop. Outside that specific history, cancer isn't the risk the current evidence points you toward worrying about.

Are Wegovy's side effects different for women — especially in perimenopause?

This is the detail most generic side-effect lists skip, and it's worth stating plainly: yes, there's real sex-disaggregated data here, not just a hunch. A pooled analysis across Wegovy's Phase 3a trials found 90.5% of women reported some adverse event, versus 83.4% of men; 9.5% of women had a serious adverse event versus 9.1% of men; and 6.1% of women stopped treatment permanently because of a side effect, versus 4.6% of men.

That gap isn't random. Women also lost meaningfully more weight than men across the STEP program, and GI side effects track closely with how much weight someone is losing. More effect, more side effect, in other words — not a sign that Wegovy behaves less safely in women's bodies.

Where it gets genuinely harder to untangle is perimenopause itself. Fatigue, stomach upset, and disrupted sleep already show up on their own during the menopause transition, with no medication involved, so a woman starting Wegovy in her 40s is sorting out two overlapping symptom sets at once, not one. A rough rule of thumb: GI symptoms that track tightly with your dose increases and ease within a week or two are more likely Wegovy; fatigue or mood shifts that show up independent of dosing, or alongside hot flashes and cycle changes, more likely trace back to the menopause transition itself running in parallel.

Two areas deserve specific attention past 40. In a trial of adults at increased fracture risk — a population weighted toward postmenopausal women — semaglutide was associated with a measurable drop in bone mineral density at 52 weeks: roughly 2.6% at the hip and 2.1% at the spine, compared with placebo. Mechanically, that lines up with what's already happening in perimenopause — less mechanical loading on bone as weight drops, and less peripheral estrogen production from fat tissue right as ovarian estrogen is already declining. Weight-bearing and resistance exercise, and a baseline bone density scan if you're over 50 or already have risk factors, are worth raising with your provider before you start.

Muscle tells a similar story. In the DXA sub-study of STEP 1, roughly 40% of the weight participants lost was lean body mass rather than fat — a pattern seen across the GLP-1 class generally, not unique to Wegovy. That matters more when perimenopause is already eroding muscle on its own. For the research behind that finding and what actually helps protect muscle during treatment, see GLP-1s and muscle loss in perimenopause.

What doesn't exist yet: a trial that specifically breaks down Wegovy's side-effect profile by menopausal status rather than just sex. The women in STEP and SELECT span a wide age range, and nobody has published a pre- versus post-menopausal side-by-side comparison. That's a real gap, not a reason to assume a hidden danger or a false reassurance — it's simply thinner data than the sex-based numbers above, worth naming honestly rather than inventing a distinction the research hasn't drawn yet.

Which side effects need same-day medical attention?

The everyday nausea-and-bloating cluster above is one category. This is a different one — symptoms that overlap with the serious risks and are worth same-day attention rather than a routine follow-up message.

• Severe, persistent abdominal pain, especially radiating to your back, with or without vomiting — possible pancreatitis
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes — possible gallbladder involvement
• A new lump or swelling in your neck, persistent hoarseness, trouble swallowing, or shortness of breath — the symptoms the FDA specifically asks prescribers to counsel on given the thyroid warning
• Signs of severe dehydration — sharply reduced urination, dizziness on standing, confusion — especially after several days of vomiting or diarrhea
• Signs of severe low blood sugar if you also take insulin or a sulfonylurea — shakiness, confusion, sweating that doesn't resolve with food
• Sudden vision changes, particularly if you also have type 2 diabetes

What are the long-term side effects of Wegovy — and what's still being studied?

Wegovy has more long-term data behind its actual approved use than people often assume. STEP 1 ran 68 weeks; its extension followed participants further to track what happens after stopping; SELECT followed more than 17,000 people with cardiovascular disease for several years. That's a meaningfully longer runway of safety data, in the population Wegovy is actually approved for, than Ozempic had when it was first used off-label for weight loss.

A few questions are still genuinely open: how sustained rapid weight loss affects bone density and muscle mass over many years, beyond the roughly one-year data available now; whether the rodent-based thyroid signal holds any relevance as more years of human exposure accumulate; and what happens metabolically for people who eventually stop the medication after using it long-term. The STEP 1 extension found weight and metabolic markers moved back in the other direction after stopping — more a fact about the mechanism than a hidden danger. The oral tablet, approved in December 2025, simply doesn't have years of real-world use behind it yet. It's the newest format of an established drug, not an unknown one.

How do you manage the common side effects?

A handful of practical habits cover most of what shows up in the first weeks and months.

• Respect the titration schedule — dose increases are spaced out specifically to give your gut time to adjust; asking to move faster tends to backfire
• Go smaller and lower-fat with meals — semaglutide already slows digestion, and a large or fatty meal on top of that is the most common nausea trigger
• Stay ahead of hydration, especially during a rough stretch of vomiting or diarrhea — the biggest lever against the dehydration-driven kidney concern above
• If you're on the tablet, keep the same daily timing and the 30-minute wait before food or other medications — inconsistent timing can make nausea less predictable, not less common
• Track when nausea tends to peak after a dose increase — some people do better adjusting meal timing or moving a dose earlier in the day

Where to get Wegovy with support if a side effect isn't settling

If a symptom is dragging past the first couple of months, or you'd rather have labs confirm what's going on than guess, the differences between providers show up less in the sticker price and more in what's already included once you're enrolled.

Ro Body bundles labs and an insurance concierge into its membership, so a side effect that needs a blood panel is already accounted for rather than a new bill. NovoCare is Novo Nordisk selling directly to you — the tablet from $149 a month, the pen from a $199 introductory rate — with no telehealth membership layered on top. What it doesn't include is a clinician relationship or bundled labs, so if a symptom needs bloodwork, that's a separate step you arrange yourself.

Mochi Health and Henry Meds both dispense compounded semaglutide rather than the branded Wegovy pen or tablet — the same active molecule, prepared by a licensed 503A pharmacy rather than manufactured and FDA-approved by Novo Nordisk, worth knowing going in. Mochi's roughly $178 a month doesn't rise as you titrate; Henry Meds' flat $249 or $297 a month works the same way, though its own pricing pages describe multi-month prepay tiers alongside that flat rate, so confirm which applies before enrolling.